Berberine
Catalog No: CFN98049
Berberine has neuroprotective, antidepressant, antineoplastic, and anti- fibrosis activities; it is a potent oral hypoglycemic agent with beneficial effects on lipid metabolism, it may as a broad-spectrum anti-microbial medicine, a complementary therapeutic agent for HIV/AIDS; it also may be one of the targeted therapeutic agents that can restore barrier function in intestinal disease states.Berberine is used in histology for staining heparin in mast cells. As a natural dye, berberine has a colour index of 75160.
Berberine hydrochloride
Catalog No: CFN99562
Berberine hydrochloride has anticancer, antifungi, anti-inflammatory, and anti-oxidant activities, it can significantly attenuate neutrophil infiltration, suppress myeloperoxidase activity, decrease NO, TNF-αand IL-1βproduction, inhibits the phosphorylation of the NF-κB p65 subunit and the degradation of its inhibitor, IκBα.
Bergapten
Catalog No: CFN98766
Bergapten is a psoralen that can be photoactivated and is capable of crossing-linking DNA, covalently modifying proteins and lipids, and consequently inhibiting cell replication. Bergapten has anti-inflammatory and anti-tumor agent, it exhibits significant inhibition of the production of pro-inflammatory cytokines, namely tumour necrotic factor-α(TNF-α) and interleukin-6 (IL-6) by peripheral blood mononuclear cells (PBMCs) stimulated with lipopolysaccharide in a concentration-dependent manner. Bergapten effectively prevents LPS-induced osteoclastogenesis, bone resorption and survival via apoptotic response of osteoclasts and their precursors.
Bergenin
Catalog No: CFN98724
Bergenin is a potent antinarcotic agent, has antiviral ,antifungal, antiarrhythmic, antitumor, antiinflammatory, potent immunomodulatory, antitussive, antiulcerogenic,anti-plasmodial, anti-hepatotoxic and wound healing activities. Bergenin has antidiabetic activity, could be classified as a new group of α-glucosidase inhibitors. Bergenin reduces the expression of NO, TNF-α, IL-1β, and IL-6 proinflammatory cytokines by inhibiting the activation of the NF-κB and MAPKs signaling pathways, and it may represent a novel treatment strategy for mastitis.
Beta,beta-Dimethylacrylalkannin
Catalog No: CFN90626
Beta,beta-Dimethylacrylalkannin has radical scavenging activity, it exhibits inhibitory activities on PTP1B with IC50 values of 0.36±0.08 umol·L-1, it may be a new type of leading compounds for the treatment of diabetes. Beta,beta-Dimethylacrylalkannin has great potential as topo I inhibitors compared to other compounds and CPT-11, with 2-3uM inhibition value. Beta,beta-Dimethylacrylalkannin can be potential therapeutics against tumor cell growth because of its unique DNA damaging abilities additional to enzyme inhibition similar to those of doxorubicin.
